{"id":"W4387836902","doi":"10.1016/j.annonc.2023.09.556","title":"379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; Santé Montérégie; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; London Health Sciences Centre; Western University","funders":"Daiichi-Sankyo; Daiichi Sankyo Europe; AstraZeneca","keywords":"Medicine; Internal medicine; Tolerability; Oncology; Adverse effect; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001398112,0.0006074297,0.001892918,0.0006325598,0.0004014094,0.00003095384,0.0005578153,0.0002615973,0.0011532],"category_scores_gemma":[0.00182996,0.000522348,0.0003173078,0.00172611,0.0004106582,0.0002334177,0.0003219174,0.0004808326,0.0001547087],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008445803,"about_ca_system_score_gemma":0.00380972,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01763586,"about_ca_topic_score_gemma":0.01852836,"domain_scores_codex":[0.9941622,0.0005545832,0.00155882,0.00137026,0.0009502352,0.001403913],"domain_scores_gemma":[0.9941214,0.001840872,0.0006252794,0.001255537,0.001514509,0.0006424098],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1308916,0.02631281,0.001923229,0.0003896229,0.005821954,0.002833846,0.009422798,0.001289308,0.004811675,0.0000608414,0.11107,0.7051723],"study_design_scores_gemma":[0.3280743,0.235845,0.01243507,0.001313806,0.002144082,0.0002986389,0.00878179,0.01088917,0.05240064,0.005321602,0.3408374,0.001658461],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9365632,0.0008141214,0.0001336783,0.03910432,0.0005372397,0.007322744,0.01407399,0.0002341152,0.001216604],"genre_scores_gemma":[0.9840168,0.003121522,0.001046158,0.001210399,0.0003980848,0.002777559,0.002171159,0.0001549542,0.005103301],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7035139,"threshold_uncertainty_score":0.9997599,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1913055246931296,"score_gpt":0.5132972358923467,"score_spread":0.321991711199217,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}